Mirum Pharmaceuticals (MIRM) Net Income towards Common Stockholders (2019 - 2026)

Mirum Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$790.2 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 5283.63% year-over-year to -$790.2 million in Q1 2026; TTM through Mar 2026 was -$798.8 million, a 932.9% decrease from a year earlier, with the FY2025 full-year figure at -$23.4 million, up 73.43% from the prior year.
• Net Income towards Common Stockholders fell to -$790.2 million in Q1 2026 per MIRM's latest filing, from -$5.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $2.9 million in Q3 2025 and bottomed at -$790.2 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is -$25.3 million (2024), against an average of -$70.6 million.
• Across the five-year window, Net Income towards Common Stockholders soared 120.41% in 2025 and sank 5283.63% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then surged by 33.28% to -$23.8 million in 2024, then soared by 75.91% to -$5.7 million in 2025, then slumped by 13689.79% to -$790.2 million in 2026.
• Per Business Quant, the three latest MIRM Net Income towards Common Stockholders figures stand at -$790.2 million (Q1 2026), -$5.7 million (Q4 2025), and $2.9 million (Q3 2025).